Table 3.

Baseline characteristics of patients stratified by race/ethnicity treated with home HD at the time of initiation of home HD

Variable	White	Black	Hispanic	Asian	Other
No. of subjects	1,753	525	139	61	58
Initial modality, %a
In-center HD	65	74	71	58	67
PD	3	5	3	0	0
Home HD	31	21	26	42	33
Interval from start of dialysis to treatment with modality, d	243 [85–489]	375 [158–697]	291 [112–789]	224 [45–459]	320 [111–648]
Age, yr	55±14	47±12	47±15	48±15	51±15
Men, %	65	68	67	62	72
Primary health insurance, %
Medicare	41	33	39	38	52
Medicaid	3	4	5	5	5
Initially uninsured	2	3	2	3	0
Veterans Affairs	1	2	1	0	0
Otherb	53	58	53	54	43
Cause of ESRD, %
Diabetes	35	30	41	39	43
Hypertension	18	38	19	18	28
Glomerular disease	18	20	19	28	7
Other	29	12	21	15	22
H/o previous transplant, %	6	7	5	7	2
Comorbidities, %
Diabetes	60	60	66	62	60
Hypertension	70	85	68	75	69
Congestive heart failure	50	50	51	41	48
Atherosclerotic heart disease	27	25	31	30	19
Other cardiovascular	23	20	23	25	14
Dyslipidemia	44	46	41	48	33
Access type at start of home HD
Central venous catheter	25	19	23	18	19
AV fistula	59	61	63	64	67
AV graft	8	13	8	11	5
Unknown	8	7	6	7	9
Baseline body mass index, kg/m2	30±8	30±8	29±7	26±5	29±7
Laboratory variables from first 91-d period of treatment with home HD
Hemoglobin, g/dl	11.2±1.3	11.0±1.3	11.4±1.3	11.1±1.0	11.0±1.3
Iron saturation, %	25 [20–33]	26 [21–32]	27 [23–32]	25 [21–33]	25 [22–31]
Serum ferritin, ng/ml	351 [192–594]	403 [244–644]	370 [206–640]	343 [167–662]	316 [140–678]
Serum albumin, g/dl	3.9±0.5	4.0±0.4	4.1±0.4	4.0±0.4	4.0±0.4
Urea reduction ratio, %	42±9	40±8	42±8	44±10	42±11
Serum calcium, mg/dl	8.9±0.6	8.9±0.6	8.9±0.6	8.7±0.6	8.9±0.6
Serum phosphorous, mg/dl	5.1±1.2	5.0±1.1	5.2±1.2	5.5±1.2	5.1±1.3
Parathyroid hormone, pg/ml	305 [191–477]	502 [319–742]	346 [195–493]	425 [259–644]	290 [189–443]
Alkaline phosphatase, IU/L	79 [62–106]	78 [63–103]	77 [65–105]	80 [61–118]	73 [60–107]
Hemoglobin A1C, %	6.7 [5.8–7.8]	6.8 [5.8–8.4]	6.5 [5.7–7.8]	6.5 [5.7–7.9]	6.1 [5.7–7.0]
Potassium, mEq/L	4.4±0.6	4.3±0.6	4.4±0.6	4.6±0.5	4.4±0.5
Bicarbonate, mEq/L	24±2	24±3	23±2	23±3	23±3
iv Medications in first 91-d period of treatment with home HD
Cumulative iron, mg/mo	0 [0–300]	50 [0–400]	0 [0–200]	100 [0–200]	200 [0–400]
ESA median week dose, units	5097 [1650–12,099]	4872 [1941–11,880]	5371 [2200–11,611]	2438 [0–8800]	4180 [1532–11,313]
Geographic location, %
Northeast	17	15	13	13	21
Midwest	28	24	12	20	9
West	20	8	40	48	47
South	35	53	35	20	24
Year of incidence, %
2007	24	30	36	16	28
2008	27	22	24	36	26
2009	22	27	15	25	17
2010	18	14	14	13	17
2011	10	7	11	10	12

Data are presented as means±SDs, medians [interquartile ranges], or proportions where appropriate. H/o, history of; AV, arteriovenous; ESA, eryhropoiesis stimulating agents.

^aOf patients with an assigned modality during the first 91-day period of dialysis (n=1896).

^bIncludes Medicare Advantage plans, managed care Medicaid, and employer–based health insurance.